Article
Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations.
BMC cancer - 31 Oct 2009
Preto Ana, Gonçalves Joana, Rebocho Ana P, Figueiredo Joana, Meireles Ana M, Rocha Ana S, Vasconcelos Helena M, Seca Hugo, Seruca Raquel, Soares Paula, Sobrinho-Simões Manuel
Abstract excerpt
BACKGROUND: Thyroid carcinomas show a high prevalence of mutations in the oncogene BRAF which are inversely associated with RAS or RET/PTC oncogenic activation. The possibility of using inhibitors on the BRAF pathway as became an interesting therapeutic approach. In thyroid cancer cells the target molecules, implicated on the cellular effects, mediated by inhibition of BRAF are not well established. In order to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.